AzTrials
AzTrials

Skin GraftMATRIGREFFENCT02090361

Efficacy of Collagen-elastin Dermal Substitute in the Treatment of Loss of Cutaneous Substances With Skin Grafts

A study testing skin graft in people with Skin Graft and Collagen -Elastin Matrix, run by University Hospital, Rouen at 4 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In reconstructive surgery , most losses of cutaneous substance require the use of a thin skin graft . This technique allows epidermization of the defect by applying a thin layer of autologous epidermis. It does not reconstitute the injured skin. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Skin Graft, Collagen -Elastin Matrix
What is being tested?
skin graft
Type of treatment
Surgery or procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
92 participants
Where
4 sitesFrance
Study dates
18 Jun 2014to 26 Feb 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Aged over 18
  • Signed informed consent
  • Patients with loss of cutaneous substance of at least 15 cm2
  • Patient Without bone exposure, vascular, joint or tendon
  • Eligibility for surgical treatment by skin graft
  • Loss of substance trauma (avulsion, burns) or surgery (skin excision)

Who cannot join

  • Patient with a chronic wound
  • Wound superinfected
  • Patient unable for local or general skin graft
  • Patient with an old or a recent skin injury strictly contralateral to the graft site.
  • Patient unable to consent

Trial locations and contacts

4 sites in 1 country.

France4 sites
  • CHU d'Amiens

    Amiens

  • CHU de Caen

    Caen

  • CHU de Lille

    Lille

  • UH Rouen

    Rouen, 76031

Other trials in France

About this study

In reconstructive surgery , most losses of cutaneous substance require the use of a thin skin graft . This technique allows epidermization of the defect by applying a thin layer of autologous epidermis. It does not reconstitute the injured skin. Transplants cause retractile scars, adherent to the deep plan, that may require revision surgery . Since a decade , dermal matrices are mainly used in burned skin centers . The collagen -elastin matrix has the advantage to set up in the same operation that the skin graft and contain elastic fibers , two assets which improve the results of skin grafting.

Objective:

Read more

Evaluation of the clinical efficacy of the addition of a dermal matrix to skin graft on Skin Foldability, at day 360.

Methodology:

This is a multicenter randomized study (CHU Caen , Amiens, Rouen and Lille)

Conduct of the study :

The transplant will be performed according to the protocol defined between inter -region surgeons. The implementation of the dermal matrix will be in the same surgical technique as thin skin graft ( group 1 ) or the thin skin graft will be performed alone ( group 2) time .

Evaluation Criteria Main : Skin Foldability ( Uf ) assessed grafted site will be compared to the opposite side ungrafted evaluated at Day 360 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH).

To achieve the main objective, it is planned to compare the ratio between Uf graft site and the opposite healthy site between two groups: skin + matrix graft , or skin graft only. Thus, the Wilcoxon test for independent samples will be used to settle bilateral formulation between the null hypothesis ( there is no difference between the two groups ) and the alternative hypothesis ( there is a difference between the two groups ) . In determining the overall risk of first species to 5% and the power of this test to detect the 90% expected under the alternative hypothesis difference should be the main criterion for evaluating at least 59 patients in each group so 118 patients total.

Prospect If the contribution of a dermal matrix in loss of skin substances improves skin pliability and reduces pain , functional and aesthetic sequelae grafts thin skin , the dermal matrix may be proposed as a complementary treatment in these indications.

Being tested
skin graft
Keywords
collagen -elastin matrix, skin graft, loss of cutaneous substance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • skin graftProcedure or surgery

    Epidermization of the defect by applying a thin layer of autologous epidermis

Study groups in NCT02090361
Study groupRoleWhat they receive
skin graft with dermal matrixExperimentalEpidermization of the defect by applying a thin layer of autologous epidermis with addition of a dermal matrix
Receives: Procedure: skin graft
skin graft - classic procedurePlacebo comparatorEpidermization of the defect by applying a thin layer of autologous epidermis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Skin Foldability ( Uf )

    Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D360 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH).

    Measured: Day 360

Secondary outcomes (19)
  1. Skin Foldability ( Uf )

    Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D180 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH)

    Measured: Day 180

  2. Skin Foldability ( Uf )

    Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D90 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH)

    Measured: Day 90

  3. Pain on the grafted site

    Assessment of pain on the grafted site EVA at Day 7

    Measured: D7

  4. pain on the grafted site

    Assessment of pain on the grafted site at Day 15

    Measured: Day 15

  5. pain on the grafted site

    Assessment of pain at the grafted site EVA to D30

    Measured: Day 30

  6. pain on the grafted site

    Assessment of pain at the grafted site EVA at D30

    Measured: Day 90

  7. pain on the grafted site

    Assessment of pain at the grafted site EVA at Day 180

    Measured: Day 180

  8. pain on the grafted site

    Assessment of pain at the grafted site EVA at Day 360

    Measured: Day 360

  9. tolerance of matriderm use

    Occurrence within 360 days of a local complication requiring reoperation

    Measured: Day 360

  10. Area healed

    Evaluation of the percentage of area healed at Day 7

    Measured: Day 7

  11. Area healed

    Evaluation of the percentage of area healed at Day 15

    Measured: Day 15

  12. Area healed

    Evaluation of the percentage of area healed at Day 30

    Measured: Day 30

  13. Assessment of functional effects

    Assessment of functional effects of the scar on the patient 's daily activities defined at Day 30

    Measured: Day 30

  14. Assessment of functional effects

    Assessment of functional effects of the scar on the patient 's daily activities defined at Day 90

    Measured: Day 90

  15. Assessment of functional effects

    Assessment of functional effects of the scar on the patient 's daily activities defined at Day 180

    Measured: Day 180

  16. Assessment of functional effects

    Assessment of functional effects of the scar on the patient 's daily activities defined at Day 360

    Measured: Day 360

  17. Aesthetic sequelae evaluation

    Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 90

    Measured: Day 90

  18. Aesthetic sequelae evaluation

    Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 180

    Measured: Day 180

  19. Aesthetic sequelae evaluation

    Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 360

    Measured: Day 360

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Mar 2014 (estimated)
  2. Study start18 Jun 2014
  3. Primary completion26 Feb 2019
  4. Study completion26 Feb 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Enrolment
92 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02090361
Sponsor's protocol ID
2013/0008/HP
Acronym
MATRIGREFFE
Status last verified
Feb 2026
First submitted
14 Mar 2014
Last updated
13 Feb 2026
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing skin graft in people with Skin Graft and Collagen -Elastin Matrix, run by University Hospital, Rouen at 4 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Skin Foldability ( Uf ) (time frame: Day 360). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in